Fulfilling the promise of medicine for the developing world
OneWorld SpotlightRSS
- May 28, 2013
Antidiarrheal drug candidate moves to next phase of clinical study
Our investigational new drug developed to treat acute secretory diarrhea is entering the next phase of clinical development following the successful completion of clinical studies in the United States. Read full press release. - May 10, 2013
Semisynthetic artemisinin prequalified by WHO
WHO’s decision means semisynthetic artemisinin has been evaluated and accepted for use in the manufacture of active pharmaceutical ingredients and finished pharmaceutical products. Prequalification also creates a simplified process for manufacturers using semisynthetic artemisinin in their products to obtain regulatory acceptance, possibly accelerating the availability of malaria treatments on the market. Read full press release. - May 6, 2013
PATH to test new formulation of oral rehydration solution
PATH’s Drug Development program has launched a phase 2 clinical trial in Bangladesh to test a new formulation of oral rehydration solution (ORS), a therapy that is being evaluated for reversing dehydration that results from severe diarrhea caused by diarrheal disease. Read full announcement. - April 11, 2013
A pivotal milestone in the fight against malaria
Sanofi and PATH announce the launch of large-scale production of semisynthetic artemisinin against malaria. Read full press release.
Voices From the Field
Drug Development Blog
Keep up-to-date with our efforts on our blog.
PATH-OWH Affiliation
In December 2011, OneWorld Health became a drug development affiliate of PATH, an international nonprofit organization that transforms global health through innovation. Read full press release here.
To learn more about PATH, visit www.path.org.